Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: William Rastetter, Ajay Bansal


Regulus has appointed William Rastetter to its board of directors. Rastetter is currently chairman of the board of Illumina, Fate Therapeutics, Neurocrine Biosciences, and Receptos. He holds a PhD and MA in chemistry from Harvard University.

Onconova has appointed Ajay Bansal chief financial officer. Bansal most recently served as chief financial officer for Complete Genomics. He has also served as chief financial officer and executive vice president of corporate and business development for Lexicon Therapeutics and Tercica. He has also worked in strategy and marketing for Novartis Pharmaceuticals and held positions at consulting firms such as McKinsey & Company. He holds master's degrees in management and operations research from Northwestern University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.